Mannitol Viaflo Baxter (Mannitol)

Mannitol works by creating an osmotic gradient in the renal tubules that prevents water reabsorption, leading to increased urine output. The same osmotic effect draws water out of brain and eye tissues, decreasing their volume and pressure. This dual action helps manage fluid overload and pressure‑related complications.

The dose of Mannitol Viaflo Baxter is determined by the prescribing clinician based on the patient’s condition, weight, renal function and response to therapy. Dosing regimens are individualized and administered under medical supervision; the product label provides guidance for preparation and infusion rates, but the final prescription is set by the healthcare professional.

Safety data for Mannitol in pregnancy and lactation are limited, and the drug is generally classified as use‑only if clearly needed. The potential benefits must be weighed against unknown risks to the fetus or infant. Healthcare providers should evaluate each case individually and consider alternative therapies when possible.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if required—and assistance with import documentation.

Unlike loop or thiazide diuretics that act on specific nephron segments, Mannitol is an osmotic agent that draws water into the tubular lumen, producing a rapid, volume‑independent diuresis. It is particularly effective for reducing intracranial and intraocular pressure, whereas conventional diuretics are primarily used for chronic fluid overload and hypertension management.

Mannitol Viaflo Baxter should be stored at 2‑8 °C in a refrigerator, protected from light, and kept in its original packaging to maintain sterility. Do not freeze or shake the solution. Before use, inspect the vial for particulate matter or discoloration and allow it to reach room temperature if required for infusion.

The product is supplied as a sterile intravenous solution and is administered by slow infusion through a suitable venous access under medical supervision. The infusion rate is adjusted according to the clinical indication and patient response, with continuous monitoring of vital signs, urine output and electrolyte levels throughout the treatment period.

The most serious risks include acute renal failure, especially in patients with pre‑existing kidney impairment, pulmonary edema from fluid overload, severe electrolyte disturbances such as hypernatremia or hypokalemia, and anaphylactic reactions. Prompt recognition and monitoring are essential to mitigate these potentially life‑threatening complications.

Mannitol is contraindicated in patients with known hypersensitivity to Mannitol, severe dehydration, active intracranial bleeding, uncontrolled heart failure, or severe renal impairment where diuresis could worsen kidney function. It should also be used with caution in individuals with electrolyte imbalances, uncontrolled hypertension, or those receiving concurrent nephrotoxic medications.